Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;37:1045-1046

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smulyan, H.
Right arrow Articles by Mose, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smulyan, H.
Right arrow Articles by Mose, A.

(Hypertension. 2001;37:1045.)
© 2001 American Heart Association, Inc.


In Memoriam

David H.P. Streeten, MB, DPhil, FRCP

Harold Smulyan; Arnold Mose

*    Introduction
 
David Streeten was born, educated, and began his life’s work in South Africa. He distinguished himself early by graduating with distinction from the University of South Africa in Bloemfontein and with first-class honors from the Medical School at the University of Witwatersrand. After 2 years as a house officer, he moved to the University of Oxford, where he obtained his DPhil degree while collaborating extensively with E.M. Vaughn Williams. Although this experience launched his research career, the subject of his investigations, intestinal motility, was never revisited. From Oxford, he came to the United States, where he trained with George Thorn in Endocrinology at the Peter Bent Brigham Hospital. There, his research centered about the actions of corticotropin and hydrocortisone. His first full-time faculty position was in Ann Arbor at the University of Michigan as an Assistant Professor in the Division of Endocrinology and Metabolism. While working there with Drs Jerome Conn and Stefan Fajans, he established a novel bioassay for the newly discovered aldosterone. This assay was used to make the first confirmed diagnosis of primary aldosteronism as a new secondary cause of hypertension. While in Ann Arbor, he also became interested in periodic paralysis, diabetes, and autonomic control of the circulation, which occupied much of his research attention for the rest of his career. In 1960, we had the good fortune to recruit him to the University Hospital of the State University of New York at Syracuse, where he began and led the Endocrinology Division in the Department of . . . [Full Text of this Article]